1. Home
  2. RSF vs SER Comparison

RSF vs SER Comparison

Compare RSF & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RiverNorth Capital and Income Fund

RSF

RiverNorth Capital and Income Fund

SELL

Current Price

$14.06

Market Cap

58.6M

Sector

Finance

ML Signal

SELL

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$1.39

Market Cap

56.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RSF
SER
Founded
2016
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.6M
56.4M
IPO Year
2015
2024

Fundamental Metrics

Financial Performance
Metric
RSF
SER
Price
$14.06
$1.39
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $9.50
AVG Volume (30 Days)
6.3K
★ 67.7K
Earning Date
01-01-0001
11-12-2026
Dividend Yield
★ 10.61%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.04
$1.14
52 Week High
$15.07
$4.26

Technical Indicators

Market Signals
Indicator
RSF
SER
Relative Strength Index (RSI) 36.21 34.43
Support Level N/A $1.33
Resistance Level $14.70 $2.13
Average True Range (ATR) 0.10 0.30
MACD -0.00 -0.02
Stochastic Oscillator 17.65 14.18

Price Performance

Historical Comparison
RSF
SER

About RSF RiverNorth Capital and Income Fund

RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.

Share on Social Networks: